Alcohol Dependence & Withdrawal

1. Clinical Overview

Summary

Alcohol use disorder (AUD) is a chronic, relapsing neurobiological condition characterised by compulsive alcohol consumption, loss of control over intake, and emergence of a negative emotional state during abstinence. [1] The DSM-5 reconceptualised alcohol-related disorders as a single spectrum ranging from mild to severe, replacing the previous distinction between abuse and dependence. [2]

Alcohol withdrawal syndrome (AWS) represents a hyperexcitable state that occurs following abrupt cessation or significant reduction in alcohol consumption after prolonged heavy use. The syndrome ranges from mild symptoms (tremor, anxiety, insomnia) to life-threatening complications including generalised tonic-clonic seizures and delirium tremens. [3] Without appropriate treatment, delirium tremens carries mortality rates of 5-15%, reduced to less than 1% with modern intensive care and pharmacotherapy. [4]

Management of AWS requires systematic assessment using validated tools (CIWA-Ar), parenteral thiamine replacement to prevent Wernicke's encephalopathy, and benzodiazepine-based detoxification using either fixed-dose or symptom-triggered protocols. [5] Long-term recovery requires an integrated approach combining pharmacotherapy (acamprosate, naltrexone, or disulfiram), psychological interventions, and engagement with mutual support groups. [6]

Key Clinical Facts

Clinical Pearls

Thiamine BEFORE Glucose: Always administer IV thiamine before any glucose-containing fluids in at-risk patients. Glucose oxidation depletes thiamine reserves and can precipitate or worsen Wernicke's encephalopathy. This is one of the most preventable iatrogenic catastrophes in medicine. [9]

The 48-72 Hour Window: Delirium tremens typically develops 48-72 hours after the last drink, peaking at 72-96 hours. Patients who appear stable at 24 hours may still deteriorate significantly — never discharge a high-risk patient before 72 hours of observation. [3]

The Concealed Drinker: Hospital inpatients frequently underreport alcohol consumption. Any patient with unexplained tremor, confusion, diaphoresis, or agitation 2-3 days post-admission should be assessed for AWS. Up to 25% of general medical inpatients have significant alcohol problems. [8]

Kindling Phenomenon: Each episode of alcohol withdrawal increases the severity of subsequent withdrawals due to neuroadaptive changes. Patients with previous complicated withdrawal (seizures, DTs) are at substantially higher risk of severe withdrawal. [11]

CIWA-Ar Threshold: A CIWA-Ar score ≥10 indicates the need for pharmacological treatment. Symptom-triggered therapy guided by CIWA-Ar reduces total benzodiazepine dose by 60% and shortens treatment duration compared to fixed-dose regimens. [5]

Why This Matters Clinically

Alcohol withdrawal is one of the most common preventable causes of morbidity and mortality in hospitalised patients. Early recognition and treatment prevent seizures (which occur in 3-7% of untreated withdrawal), aspiration, rhabdomyolysis, and death. [3] Wernicke's encephalopathy affects up to 2.8% of alcohol-dependent patients and is preventable with parenteral thiamine, yet 80% of cases are missed antemortem. [9] Once Korsakoff's syndrome develops, the amnestic deficits are irreversible in approximately 75% of patients. [12]

The integration of alcohol care teams in acute hospitals has been shown to reduce 30-day readmission rates by 21% and length of stay by 2.4 days, demonstrating that systematic intervention improves outcomes and reduces healthcare costs. [13]

---

2. Epidemiology

Incidence & Prevalence

Global Burden:

Alcohol use contributes to 3 million deaths annually worldwide (5.3% of all deaths) and 132.6 million disability-adjusted life years (DALYs), representing 5.1% of the global burden of disease. [1] Alcohol is the leading risk factor for premature mortality and disability in the 15-49 age group globally. [1]

United Kingdom:

Alcohol Withdrawal Syndrome:

Demographics

Risk Factors for AUD

Genetic Factors (40-60% heritability):

• Family history of AUD (3-4x increased risk in first-degree relatives) [15]
• Polymorphisms in ADH1B and ALDH2 genes (protective in Asian populations) [15]
• Variants in GABRA2, CHRM2, and other neurotransmitter pathway genes [2]

Environmental Factors:

• Early age of first drink (less than 15 years: 4x risk of AUD vs > 21 years) [2]
• Childhood trauma and adverse childhood experiences (ACEs) [2]
• Peer influences and social norms around drinking [15]
• Low cost and high availability of alcohol [1]

Psychiatric Factors:

• Pre-existing anxiety or depression [2]
• Conduct disorder and antisocial personality traits [2]
• ADHD (associated with earlier onset and more severe AUD) [2]
• Post-traumatic stress disorder [2]

Risk Factors for Severe Withdrawal and Delirium Tremens

Predictors of Severe AWS/DT: [3,10]

PAWSS (Prediction of Alcohol Withdrawal Severity Scale): [16]

The PAWSS is a validated 10-item screening tool that identifies patients at risk of complicated AWS requiring pharmacological intervention:

• Score ≥4: Sensitivity 93.1%, Specificity 99.5% for moderate-severe AWS
• Includes: prior complicated withdrawal, prior detox, prior seizures/DTs, combined drug use, BAC > 200 mg/dL, signs of intoxication, signs of withdrawal

---

3. Pathophysiology

Neurobiological Mechanisms

Alcohol's Acute Effects on Neurotransmission:

Alcohol produces its intoxicating effects through complex interactions with multiple neurotransmitter systems: [11]

1. GABA-A Receptors (Enhancement):

   • Alcohol positively modulates GABA-A receptors, particularly those containing α4, α6, and δ subunits
   • Increases chloride ion conductance → neuronal hyperpolarisation → CNS depression
   • Effects on GABA-A mediate sedation, anxiolysis, motor incoordination

2. NMDA Glutamate Receptors (Inhibition):

   • Alcohol inhibits NMDA receptor function by binding to the glycine co-agonist site
   • Reduces glutamatergic excitatory neurotransmission
   • Contributes to memory impairment and sedation

3. Dopaminergic System (Activation):

   • Increases dopamine release in nucleus accumbens (reward pathway)
   • Contributes to reinforcing properties and addiction development

4. Endogenous Opioid System (Activation):

   • Alcohol stimulates β-endorphin release
   • Contributes to euphoria and reward

Chronic Adaptation (Neuroadaptation):

With repeated exposure, the brain adapts to maintain homeostasis: [11]

1. GABA System Downregulation:

   • Reduced GABA-A receptor expression and sensitivity
   • Decreased GABAergic inhibitory tone
   • Result: Tolerance to alcohol's sedative effects

2. NMDA System Upregulation:

   • Increased NMDA receptor expression (particularly NR2B subunits)
   • Enhanced glutamatergic excitatory tone
   • Result: Tolerance to alcohol's amnestic effects

3. HPA Axis Dysregulation:

   • Chronic activation of stress response systems
   • Elevated CRF (corticotropin-releasing factor) in amygdala
   • Contributes to negative emotional state during abstinence

4. Allostatic Changes:

   • Shift from positive reinforcement (reward) to negative reinforcement (relief of dysphoria)
   • Establishment of new homeostatic "set point" requiring alcohol

Withdrawal Pathophysiology

The Hyperexcitable State:

When alcohol is abruptly discontinued, the neuroadaptive changes produce a state of CNS hyperexcitability: [3,11]

1. Glutamatergic Excess:

   • Upregulated NMDA receptors now unopposed by alcohol
   • Excessive glutamate release and excitotoxicity
   • Contributes to seizures, cell death, cognitive dysfunction

2. GABAergic Deficiency:

   • Downregulated GABA-A receptors → reduced inhibitory tone
   • Insufficient GABAergic restraint on excitatory activity
   • Contributes to anxiety, tremor, seizures

3. Autonomic Hyperactivity:

   • Noradrenergic hyperactivity (increased norepinephrine release)
   • Sympathetic overdrive
   • Tachycardia, hypertension, diaphoresis, fever

4. Dopaminergic Dysfunction:

   • Reduced dopaminergic transmission in reward circuits
   • Contributes to dysphoria, anhedonia, craving

Kindling Phenomenon:

Repeated withdrawal episodes cause progressive intensification of withdrawal severity: [11]

• Each withdrawal episode sensitises glutamatergic systems
• Increased likelihood of seizures with successive withdrawals
• Electrophysiological changes persist between episodes
• Explains why patients with prior complicated withdrawal are at highest risk

Withdrawal Timeline

Wernicke's Encephalopathy Pathophysiology

Thiamine (Vitamin B1) Deficiency: [9]

1. Causes in Alcohol Dependence:

   • Poor dietary intake (displaces nutritional calories)
   • Impaired intestinal absorption (alcohol damages gut mucosa)
   • Reduced hepatic storage and activation
   • Increased utilisation during alcohol metabolism
   • Magnesium deficiency impairs thiamine utilisation

2. Biochemical Consequences:

   • Thiamine pyrophosphate (TPP) is essential cofactor for:
     • Pyruvate dehydrogenase (glycolysis → Krebs cycle)
     • α-ketoglutarate dehydrogenase (Krebs cycle)
     • Transketolase (pentose phosphate pathway)
   • Impaired ATP production and oxidative metabolism
   • Glucose administration increases thiamine demand → can precipitate Wernicke's

3. Selective Vulnerability:

   • Periventricular regions: mammillary bodies, medial thalamus, periaqueductal grey
   • High metabolic demand and blood-brain barrier characteristics
   • Lesions cause classic clinical triad

4. Progression to Korsakoff Syndrome:

   • Without treatment, 80-85% develop Korsakoff's [12]
   • Irreversible damage to mammillary bodies and dorsomedial thalamus
   • Permanent anterograde and retrograde amnesia
   • Confabulation (fabrication of memories)

DSM-5 Alcohol Use Disorder Classification

The DSM-5 (2013) eliminated the abuse/dependence distinction, classifying AUD on a severity spectrum: [2]

DSM-5 Diagnostic Criteria (require ≥2 in 12 months):

Severity:

• Mild: 2-3 criteria
• Moderate: 4-5 criteria
• Severe: 6 or more criteria

---

4. Clinical Presentation

Symptoms of Alcohol Use Disorder

Core Features (ICD-11 Criteria for Dependence): [2]

1. Impaired control over alcohol use:

   • Onset, termination, or levels of use
   • Persistent drinking despite attempts to reduce

2. Increasing priority given to alcohol:

   • Over other activities and responsibilities
   • Progressive neglect of work, family, social obligations

3. Physiological features:

   • Tolerance (marked increase in quantity consumed)
   • Withdrawal symptoms on cessation

Associated Features:

• Drinking in the morning to relieve withdrawal symptoms ("eye-opener")
• Blackouts (anterograde amnesia during intoxication)
• Continued drinking despite medical contraindications
• Legal or interpersonal consequences related to drinking
• Unsuccessful attempts to quit or control drinking
• Loss of interest in previously enjoyed activities (anhedonia)

Alcohol Withdrawal Syndrome Presentation

Minor Withdrawal (6-24 hours):

Alcoholic Hallucinosis (12-48 hours):

• Vivid visual, auditory, or tactile hallucinations
• Key feature: Intact orientation and sensorium (not delirious)
• Patient recognises hallucinations as unreal (insight often preserved)
• Visual: Moving objects, animals, insects
• Tactile: Formication (sensation of insects crawling under skin)
• Auditory: Threatening or accusatory voices
• Resolves within 24-48 hours with treatment

Withdrawal Seizures (12-48 hours):

Delirium Tremens (48-96 hours):

Autonomic Features in DT:

• Temperature: Often > 38.5°C, may exceed 40°C
• Heart rate: > 100 bpm, often 120-150 bpm
• Blood pressure: Hypertension common; hypotension indicates severe illness
• Respiratory rate: Tachypnoea common
• Diaphoresis: Profuse, with dehydration risk

Wernicke's Encephalopathy

Classic Triad (present in only 10-16% of cases): [9]

Other Features:

• Hypotension (cardiovascular beriberi)
• Hypothermia (hypothalamic dysfunction)
• Vestibular dysfunction
• Peripheral neuropathy (dry beriberi)

Clinical Pearl: Because the full triad is present in only 10-16% of cases, a high index of suspicion is required. Any ONE feature in an at-risk patient should prompt treatment with IV thiamine. [9]

Signs on Examination

General Inspection:

• Signs of chronic liver disease: jaundice, spider naevi, caput medusae, palmar erythema, gynaecomastia
• Nutritional deficiency: muscle wasting, peripheral oedema
• Parotid enlargement (bilateral, painless)
• Dupuytren's contracture (palm)
• Rhinophyma (nasal hypertrophy)
• Bruising (coagulopathy, thrombocytopenia)

Vital Signs in Withdrawal:

• Tachycardia (HR > 100)
• Hypertension (SBP > 140 or DBP > 90)
• Fever (especially in DT)
• Tachypnoea

Neurological Examination:

• Tremor: fine tremor at rest; coarse action tremor with hands extended
• Hyperreflexia
• Nystagmus (Wernicke's)
• Ophthalmoplegia (Wernicke's)
• Gait ataxia (cerebellar or Wernicke's)
• Peripheral neuropathy (glove and stocking sensory loss)
• Confusion, disorientation (assess with 4AT or AMT)

Cardiovascular:

• Signs of alcoholic cardiomyopathy: displaced apex beat, S3 gallop, peripheral oedema

Abdominal:

• Hepatomegaly (early disease) or shrunken liver (cirrhosis)
• Splenomegaly (portal hypertension)
• Ascites (advanced liver disease)
• Caput medusae

Red Flags — Immediate Assessment Required

[!CAUTION] Red Flags Requiring Urgent Treatment:

• Seizure (may be first presentation; 30% progress to DT if untreated)
• Delirium (confusion + hallucinations + agitation = delirium tremens)
• Wernicke's triad (any one of: confusion, ataxia, ophthalmoplegia)
• Hyperthermia (temperature > 38.5°C indicates severe withdrawal)
• Cardiovascular instability (severe hypertension OR hypotension)
• Respiratory distress (aspiration, pneumonia)
• Hypoglycaemia (may mimic neurological complications)

---

5. Assessment & Screening Tools

AUDIT (Alcohol Use Disorders Identification Test)

Purpose: WHO-developed screening tool to identify hazardous, harmful drinking and possible dependence [17]

Structure: 10 items covering consumption (items 1-3), dependence (items 4-6), and consequences (items 7-10)

Scoring:

• Score 0-40 (each item 0-4)
• 0-7: Lower risk
• 8-15: Increasing/hazardous risk (brief intervention)
• 16-19: Higher/harmful risk (brief intervention + monitoring)
• ≥20: Possible dependence (referral to specialist services)

AUDIT-C (Abbreviated): First 3 questions only; score ≥5 indicates hazardous drinking

CAGE Questionnaire

Purpose: Brief 4-item screening for alcohol problems [17]

Scoring:

• Each "yes" = 1 point
• ≥2: Sensitivity 77-94%, Specificity 79-97% for alcohol problems
• ≥3: High specificity for dependence

Limitations: Detects problem drinking but not quantity/frequency; less sensitive in women, young adults, and ethnic minorities

CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised)

Purpose: Standardised assessment of withdrawal severity to guide treatment [5]

Structure: 10 items assessing withdrawal symptoms; maximum score 67

Interpretation:

Administration:

• Assess every 1-2 hours initially
• Cannot be used if patient is sedated, intubated, or unable to communicate
• Use clinical judgement in patients with comorbid psychiatric illness

SADQ (Severity of Alcohol Dependence Questionnaire)

Purpose: Measures severity of alcohol dependence [17]

Structure: 20 items covering physical withdrawal, affective withdrawal, withdrawal relief drinking, consumption, reinstatement

Scoring:

• Score 0-60
• less than 16: Mild dependence — community detox possible
• 16-30: Moderate dependence — assisted community or inpatient
• > 30: Severe dependence — inpatient detox recommended

PAWSS (Prediction of Alcohol Withdrawal Severity Scale)

Purpose: Identify hospitalised patients at risk for moderate-severe AWS requiring pharmacological treatment [16]

Structure: 10-item scale administered on admission

Items Include:

1. BAC on admission > 200 mg/dL or intoxicated
2. Evidence of increased autonomic activity
3. History of blackouts
4. History of prior seizures
5. History of prior DT
6. History of prior alcohol detox
7. History of combined substance use
8. Prior history of inability to limit drinking
9. Prior history of withdrawal symptoms
10. Consumed alcohol within 24 hours

Threshold: Score ≥4 predicts moderate-severe AWS with sensitivity 93.1%, specificity 99.5%

---

6. Investigations

Bedside Investigations

Laboratory Investigations

Biomarkers of Chronic Alcohol Use:

Imaging

---

7. Management

Management Algorithm

            ALCOHOL WITHDRAWAL SYNDROME
                        ↓
┌─────────────────────────────────────────────────────┐
│           INITIAL ASSESSMENT (A-B-C-D-E)            │
│  Airway, Breathing, Circulation, Disability, Expose │
└─────────────────────────────────────────────────────┘
                        ↓
┌─────────────────────────────────────────────────────┐
│          INVESTIGATIONS & RISK ASSESSMENT           │
│  • Bloods: FBC, LFTs, U&Es, Mg, PO4, glucose, INR  │
│  • BAL, ECG, urinalysis                             │
│  • Calculate CIWA-Ar score                          │
│  • Risk factors for severe withdrawal (PAWSS)       │
└─────────────────────────────────────────────────────┘
                        ↓
┌─────────────────────────────────────────────────────┐
│             THIAMINE (PABRINEX) - FIRST!            │
│  ⚠️ ALWAYS BEFORE GLUCOSE-CONTAINING FLUIDS         │
│                                                     │
│  Standard prophylaxis:                              │
│    1 pair IV Pabrinex TDS for 3-5 days              │
│                                                     │
│  Suspected/confirmed Wernicke's:                    │
│    2 pairs IV Pabrinex TDS for minimum 5 days       │
│    Then 1 pair OD for further 3-5 days              │
│    Then oral thiamine 100mg TDS indefinitely        │
└─────────────────────────────────────────────────────┘
                        ↓
┌─────────────────────────────────────────────────────┐
│             BENZODIAZEPINE THERAPY                  │
├─────────────────────────────────────────────────────┤
│  CIWA-Ar less than 10:                                       │
│    • Monitor only (2-4 hourly CIWA-Ar)              │
│    • PRN benzodiazepine if symptomatic              │
│                                                     │
│  CIWA-Ar 10-15 (Mild-Moderate):                     │
│    • Symptom-triggered therapy                      │
│    • Chlordiazepoxide 10-20mg PRN when CIWA-Ar > 10  │
│    • Reassess hourly                                │
│                                                     │
│  CIWA-Ar 16-20 (Moderate-Severe):                   │
│    • Symptom-triggered OR fixed-dose regimen        │
│    • Chlordiazepoxide 20-40mg 1-2 hourly PRN        │
│    • Consider HDU monitoring                        │
│                                                     │
│  CIWA-Ar > 20 OR DT OR Seizures:                     │
│    • Fixed-dose + symptom-triggered                 │
│    • IV Diazepam 10-20mg or Lorazepam 2-4mg         │
│    • ICU/HDU admission                              │
│    • May need phenobarbital if BZD-resistant        │
└─────────────────────────────────────────────────────┘
                        ↓
┌─────────────────────────────────────────────────────┐
│            SUPPORTIVE CARE                          │
│  • IV fluids (avoid glucose until thiamine given)   │
│  • Electrolyte replacement (K+, Mg2+, PO4 3-)       │
│  • Quiet, well-lit room                             │
│  • Frequent orientation and reassurance             │
│  • Nutritional support                              │
│  • VTE prophylaxis                                  │
│  • Seizure precautions                              │
└─────────────────────────────────────────────────────┘
                        ↓
┌─────────────────────────────────────────────────────┐
│        POST-WITHDRAWAL PLANNING                     │
│  • Specialist addiction referral                    │
│  • Consider pharmacotherapy for relapse prevention  │
│    - Acamprosate (first-line, hepatically safe)     │
│    - Naltrexone (effective for craving reduction)   │
│    - Disulfiram (requires high motivation)          │
│  • Psychological interventions (MET, CBT)           │
│  • Mutual support groups (AA, SMART Recovery)       │
│  • Address psychiatric comorbidity                  │
│  • Social support assessment                        │
└─────────────────────────────────────────────────────┘

Acute Management

Immediate Priorities (ABCDE Approach):

1. Airway: Assess patency; recovery position if reduced consciousness; consider intubation if GCS less than 8
2. Breathing: Oxygen if hypoxic; exclude aspiration pneumonia (CXR if tachypnoeic/hypoxic)
3. Circulation: IV access (large bore); fluids if hypovolaemic; treat hypotension
4. Disability: Glucose (AFTER thiamine); assess GCS; exclude hypoglycaemia, head injury, intracranial pathology
5. Exposure: Full examination; look for injuries, signs of liver disease, infection

IV Thiamine (Pabrinex) — CRITICAL: [9]

Administration Notes:

• Pabrinex must be given BEFORE glucose-containing fluids
• Administer IV over 30 minutes (anaphylaxis risk 1:5 million)
• IM absorption is unreliable in alcoholics (muscle wasting, poor perfusion)
• Oral absorption is impaired in alcoholics — parenteral route essential initially
• Co-prescribe magnesium (IV or oral) as thiamine pyrophosphate requires Mg2+ for activation

Benzodiazepine Regimens

Choice of Benzodiazepine: [5]

Fixed-Dose Reducing Regimen (Chlordiazepoxide):

Symptom-Triggered Therapy (CIWA-Ar Guided): [5]

Superior to fixed-dose regimens in most patients:

• Give chlordiazepoxide 10-20mg when CIWA-Ar ≥10
• Reassess CIWA-Ar 1 hour after each dose
• Repeat dosing until CIWA-Ar less than 10
• Reassess every 2-4 hours once stable
• Maximum typical dose: 400mg/day chlordiazepoxide

Advantages of Symptom-Triggered Therapy:

• 60% reduction in total benzodiazepine dose [5]
• Shortened treatment duration (median 9h vs 68h) [5]
• Individualised treatment
• Reduced over-sedation and respiratory depression

Severe/Refractory Withdrawal (ICU Setting):

If requiring very high doses (> 400mg chlordiazepoxide equivalent or not responding):

• IV diazepam 10-20mg boluses every 5-10 minutes until sedated
• Consider IV diazepam infusion (10-20mg/hr, titrated)
• Add phenobarbital 130-260mg IV if benzodiazepine-resistant
• Dexmedetomidine as adjunct (α2-agonist; reduces autonomic symptoms)
• Propofol with intubation for refractory cases

Seizure Management

Acute Withdrawal Seizures:

1. First seizure (self-terminating less than 5 min):

   • Standard seizure first aid (recovery position, protect from injury)
   • IV lorazepam 4mg (or diazepam 10mg IV)
   • Increase benzodiazepine maintenance dose
   • Do not start phenytoin (ineffective in alcohol withdrawal seizures) [10]

2. Prolonged/recurrent seizures (status epilepticus):

   • Lorazepam 4mg IV, repeat after 5-10 min if ongoing
   • If refractory: phenobarbital 10-20mg/kg IV
   • Consider intubation and propofol if refractory
   • Neurology/ICU consultation

Note: Phenytoin is NOT effective for alcohol withdrawal seizures (different mechanism from epileptic seizures) and should not be used. [10]

Delirium Tremens Management

Principles:

• ICU/HDU admission mandatory (mortality up to 5% with treatment)
• High-dose benzodiazepines (may require 500-1000mg diazepam equivalents/day)
• Aggressive fluid and electrolyte replacement
• Temperature management (cooling if hyperthermic)
• Continuous monitoring (cardiac, oxygen saturation)

Pharmacological Approach:

1. First-line: IV benzodiazepines

   • IV diazepam 10-20mg every 5-10 min until calm
   • Or IV lorazepam 2-4mg every 5-10 min
   • May require very high doses (diazepam-resistant DT)

2. Adjuncts:

   • Phenobarbital 130-260mg IV if benzodiazepine-resistant
   • Dexmedetomidine for autonomic control
   • Haloperidol 2-5mg IV for severe agitation (only with adequate benzodiazepine cover — lowers seizure threshold)

3. Refractory DT:

   • Propofol infusion with intubation
   • Paralysis if severe hyperthermia/rhabdomyolysis
   • Cooling blankets

Avoid:

• Antipsychotics alone (lower seizure threshold)
• Physical restraints (increase hyperthermia, agitation)
• Undertreatment with benzodiazepines

Electrolyte Replacement

Refeeding Syndrome Risk:

• High risk in malnourished alcoholics
• Check phosphate, magnesium, potassium before refeeding
• Start nutrition slowly (10 kcal/kg/day, increase over 4-7 days)
• Supplement thiamine, B vitamins, phosphate, magnesium, potassium

Maintenance Pharmacotherapy for Relapse Prevention

Acamprosate: [6,18]

Naltrexone: [6,18]

Disulfiram: [6,18]

Comparison of Medications:

Nalmefene (Selincro): [18]

• μ/δ opioid antagonist and κ partial agonist
• Licensed for harm reduction (reducing alcohol consumption, not abstinence)
• Dose: 18mg PRN (1-2 hours before anticipated drinking)
• Alternative when abstinence not the primary goal
• Less evidence than acamprosate/naltrexone

Psychosocial Interventions

NICE CG115 recommends psychological interventions for all patients with AUD: [8]

Mutual Support Groups:

• Alcoholics Anonymous (AA): 12-step program; abstinence-based; peer support
• SMART Recovery: Science-based; self-management focus
• Cochrane review (2020) found AA and 12-step facilitation increase abstinence rates and reduce healthcare costs [19]

Disposition & Follow-Up

Indications for Inpatient Detoxification:

• SADQ score ≥30 (severe dependence)
• History of complicated withdrawal (DT, seizures)
• Multiple previous detoxification attempts
• Significant medical comorbidity
• Significant psychiatric comorbidity with high risk
• Lack of stable home environment
• Concurrent benzodiazepine or other substance dependence
• Failed community detoxification

Indications for Community Detoxification:

• SADQ score less than 30 (mild-moderate dependence)
• No history of complicated withdrawal
• Stable home environment with support
• Motivated patient
• Access to daily monitoring (nurse-led community detox)
• No medical contraindications

Follow-Up Plan:

1. Week 1: Daily contact (community nurse or specialist team)
2. Weeks 2-4: At least twice weekly contact
3. Months 1-3: Weekly to fortnightly contact
4. Months 3-12: Monthly contact; relapse prevention pharmacotherapy review
5. Long-term: Ongoing GP follow-up; continued engagement with support services

---

8. Complications

Immediate Complications (Hours to Days)

Early Complications (Days to Weeks)

Chronic Complications of AUD

---

9. Prognosis & Outcomes

Natural History

Outcomes with Treatment

Prognostic Factors

Favourable Prognosis:

• Motivation for change (prognostic importance cannot be overstated)
• Strong social support network
• Employment and stable housing
• Engagement with addiction services
• No previous complicated withdrawal
• No concurrent substance use
• Psychiatric stability
• Early intervention

Unfavourable Prognosis:

• Previous DT or seizures (kindling)
• Multiple previous treatment episodes
• Concurrent mental health disorder
• Homelessness or social instability
• Polysubstance use
• Advanced liver disease (limits pharmacotherapy options)
• Ongoing social/domestic stressors
• Low motivation or external coercion only

---

10. Evidence & Guidelines

Key Guidelines

Landmark Trials

1. COMBINE Study (2006) [6]

2. UKATT Trial (2005) [20]

3. Cochrane Review: Benzodiazepines for Alcohol Withdrawal (2010) [5]

4. Cochrane Review: Acamprosate for Alcohol Dependence (2010) [18]

5. Cochrane Review: AA and 12-Step Facilitation (2020) [19]

Evidence Levels for Key Interventions

---

11. Exam-Focused Sections

Common Exam Questions

Written Examination (MRCPsych, MRCP):

1. "Describe the DSM-5 criteria for alcohol use disorder and its severity classification."
2. "A 52-year-old man presents with confusion and ataxia 48 hours after hospital admission. Outline your differential diagnosis and initial management."
3. "Compare and contrast symptom-triggered and fixed-dose benzodiazepine regimens for alcohol withdrawal."
4. "Discuss the evidence for pharmacological relapse prevention in alcohol use disorder."
5. "What are the neurobiological mechanisms underlying alcohol withdrawal syndrome?"

Clinical Examination (PACES, OSCE):

1. "This patient has a tremor. Please examine and present your findings."
2. "Counsel this patient about starting naltrexone for alcohol dependence."
3. "Explain alcohol detoxification to a patient's family member."
4. "Assess this patient's alcohol consumption using the AUDIT questionnaire."

Viva/Oral Examination:

1. "What are your priorities in managing a patient with suspected delirium tremens?"
2. "When would you admit a patient for inpatient alcohol detoxification?"
3. "What investigations would you request for a patient presenting with alcohol withdrawal?"

Viva Points

Opening Statement: "Alcohol use disorder is a chronic relapsing neurobiological condition characterised by compulsive alcohol consumption, loss of control, and negative emotional states during abstinence. Alcohol withdrawal syndrome results from abrupt cessation after prolonged heavy use and ranges from mild tremor and anxiety to life-threatening delirium tremens and seizures."

Key Facts to Mention:

• DSM-5 spectrum classification (mild 2-3, moderate 4-5, severe 6+ criteria)
• Withdrawal timeline: Tremor 6-12h → Seizures 12-48h → DTs 48-72h
• CIWA-Ar score ≥10 indicates need for treatment
• Thiamine BEFORE glucose — prevents Wernicke's encephalopathy
• Symptom-triggered therapy reduces benzodiazepine dose by 60%
• Acamprosate first-line for relapse prevention (NNT 9); safe in liver disease
• DT mortality less than 1% with modern ICU treatment (5-15% untreated)

Common Mistakes (What Gets You Failed)

❌ Dangerous errors:

• Giving glucose before thiamine (precipitates Wernicke's)
• Using phenytoin for alcohol withdrawal seizures (ineffective)
• Using antipsychotics alone for DT (lowers seizure threshold)
• Discharging high-risk patient before 72 hours observation

❌ Knowledge gaps:

• Not knowing DSM-5 criteria or severity classification
• Not knowing CIWA-Ar scoring and thresholds
• Confusing Wernicke's (acute, reversible) with Korsakoff's (chronic, irreversible)
• Not knowing the evidence base for acamprosate vs naltrexone

❌ Clinical reasoning errors:

• Failing to identify concealed withdrawal in hospitalised patient
• Not recognising atypical Wernicke's presentations (full triad only in 10-16%)
• Missing opportunity for brief intervention in hazardous drinkers

Model Answers

Q: "Describe your management of a patient with suspected delirium tremens."

A: "I would approach this as a medical emergency requiring immediate stabilisation and ICU/HDU admission.

Immediate priorities include securing the airway if consciousness is reduced, establishing IV access, and taking bloods including glucose, electrolytes, and LFTs. Importantly, I would give IV Pabrinex before any glucose-containing fluids.

Pharmacological management centres on benzodiazepines — I would give IV diazepam 10-20mg or lorazepam 2-4mg, repeated every 5-10 minutes until the patient is calm, as DT may require very high doses. I would add phenobarbital if benzodiazepine-resistant.

Supportive care includes aggressive IV fluids, electrolyte replacement particularly potassium and magnesium, temperature management, and continuous cardiac monitoring.

I would investigate for complications including aspiration pneumonia (CXR), rhabdomyolysis (CK), and exclude other causes of delirium such as subdural haematoma, particularly if there is a history of falls.

Once stable, I would plan for ongoing addiction specialist input, consideration of relapse prevention pharmacotherapy, and engagement with psychological support services."

---

12. Patient/Layperson Explanation

What is Alcohol Dependence?

Alcohol dependence, also called alcoholism or alcohol use disorder, is when your body and brain become so used to alcohol that you find it very difficult to control your drinking. You may need to drink more to feel the same effect (tolerance), feel unwell when you try to stop (withdrawal), and continue drinking despite knowing it is causing problems in your life.

Alcohol dependence is a medical condition, not a moral failing. It changes the chemistry of your brain in ways that make it very hard to simply "stop drinking." This is why treatment and support are so important.

What is Alcohol Withdrawal?

When someone who drinks heavily every day suddenly stops or cuts down, their body reacts because it has become used to having alcohol in the system. This reaction is called withdrawal.

Mild withdrawal (usually within 6-12 hours of stopping) includes:

• Shaking (tremor), especially of the hands
• Feeling anxious, irritable, or "on edge"
• Sweating
• Feeling sick or being sick
• Difficulty sleeping

More severe withdrawal (usually 12-72 hours) can include:

• Seeing or hearing things that aren't there (hallucinations)
• Fits (seizures)
• High temperature, racing heart, high blood pressure
• Severe confusion and agitation — this is called "delirium tremens" or "DTs" and is a medical emergency

How is Withdrawal Treated?

In hospital or at home: Depending on how severe your symptoms are and your medical history, you may be treated in hospital or at home with regular visits from nurses.

Vitamins: We give vitamin B1 (thiamine) through a drip to protect your brain. This must be given before any sugary fluids because sugar can use up the remaining vitamin and cause brain damage.

Medication for withdrawal: Tablets called chlordiazepoxide (similar to Valium) help calm the brain, reduce anxiety, and prevent fits. The dose is gradually reduced over 5-7 days.

Preventing relapse: After detox, medications like acamprosate or naltrexone can help reduce cravings and make it easier to stay alcohol-free. Counselling and support groups (like Alcoholics Anonymous) are also very helpful.

What to Expect During Recovery

• Withdrawal symptoms usually peak at 24-72 hours and improve over 5-7 days
• You may feel tired, anxious, and have trouble sleeping for a few weeks after stopping — this is normal
• Recovery is a journey — many people have "slips" but that doesn't mean failure
• With the right support, many people achieve lasting recovery

When to Seek Urgent Help

Go to A&E or call 999 if you:

• Have a fit (seizure)
• Feel very confused or see/hear things that aren't there
• Have severe shaking that won't stop
• Feel your heart racing very fast or irregularly
• Have a high temperature with severe sweating

---

13. References

Primary Guidelines

1. World Health Organization. Global status report on alcohol and health 2018. WHO; 2018. https://www.who.int/publications/i/item/9789241565639

2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). APA; 2013. doi:10.1176/appi.books.9780890425596

Key Reviews and Clinical Papers

3. Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med. 2014;371(22):2109-2113. doi:10.1056/NEJMra1407298

4. Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA. 1997;278(2):144-151. doi:10.1001/jama.1997.03550020076042

5. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev. 2010;(3):CD005063. doi:10.1002/14651858.CD005063.pub3

6. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003-2017. doi:10.1001/jama.295.17.2003

7. NHS Digital. Health Survey for England 2019: Alcohol. NHS Digital; 2021. https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england

8. National Institute for Health and Care Excellence. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence (CG115). NICE; 2011. https://www.nice.org.uk/guidance/cg115

9. Harper CG, Giles M, Finlay-Jones R. Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. J Neurol Neurosurg Psychiatry. 1986;49(4):341-345. doi:10.1136/jnnp.49.4.341

10. Jesse S, Bråthen G, Ferrara M, et al. Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand. 2017;135(1):4-16. doi:10.1111/ane.12671

11. Becker HC. Kindling in alcohol withdrawal. Alcohol Health Res World. 1998;22(1):25-33. PMID: 15706729

12. Kopelman MD, Thomson AD, Guerrini I, Marshall EJ. The Korsakoff syndrome: clinical aspects, psychology and treatment. Alcohol Alcohol. 2009;44(2):148-154. doi:10.1093/alcalc/agn118

13. Moriarty KJ, Cassidy P, Dalton D, et al. Alcohol-related disease: meeting the challenge of improved quality of care and better use of resources. Frontline Gastroenterol. 2010;1(1):2-9. doi:10.1136/fg.2010.001792

14. Public Health England. Alcohol and drug misuse and treatment statistics. PHE; 2021. https://www.gov.uk/government/collections/alcohol-and-drug-misuse-and-treatment-statistics

15. Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States. Arch Gen Psychiatry. 2007;64(7):830-842. doi:10.1001/archpsyc.64.7.830

16. Maldonado JR, Sher Y, Das S, et al. Prospective validation study of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) in medically ill inpatients. J Gen Intern Med. 2015;30(12):1833-1839. doi:10.1007/s11606-015-3325-z

17. Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995;56(4):423-432. doi:10.15288/jsa.1995.56.423

18. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;(9):CD004332. doi:10.1002/14651858.CD004332.pub2

19. Kelly JF, Humphreys K, Ferri M. Alcoholics Anonymous and other 12-step programs for alcohol use disorder. Cochrane Database Syst Rev. 2020;3(3):CD012880. doi:10.1002/14651858.CD012880.pub2

20. UKATT Research Team. Effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ. 2005;331(7516):541. doi:10.1136/bmj.331.7516.541

Further Resources

• Alcoholics Anonymous UK: https://www.alcoholics-anonymous.org.uk
• SMART Recovery: https://smartrecovery.org.uk
• Drinkaware: https://www.drinkaware.co.uk
• NHS Alcohol Support: https://www.nhs.uk/live-well/alcohol-advice
• Alcohol Change UK: https://alcoholchange.org.uk

---

Last Reviewed: 2025-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.